Drug intelligence / Profile preview

molidustat

Development stage
Phase 3
Lead developer
Bayer
Modality
Small Molecules
Administration
Oral
01

Overview

Molidustat is a small molecule drug that acts as a competitive and reversible inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH). By inhibiting HIF-PH, molidustat stabilizes hypoxia-inducible factors (HIFs), leading to increased endogenous production of erythropoietin (EPO) and subsequent stimulation of erythropoiesis (red blood cell production). It is primarily developed for the treatment of anemia associated with chronic kidney disease, both in humans and veterinary medicine. In cats, it is conditionally approved by the FDA under the brand name Varenzin-CA1 for controlling nonregenerative anemia due to chronic kidney disease. Molidustat has also been investigated in clinical trials for renal anemia in non-dialysis human subjects[3][4][5][6][7].

Brand names
Varenzin-CA1Varenzin-CA-1Varenzin-CA 1
Other names
molidustat
02

Targets

FIH-1 (Factor inhibiting hypoxia-inducible factor 1)PHD1 (Prolyl hydroxylase domain-containing protein 1)EGLN1 (Prolyl hydroxylase domain-containing protein 2)PHD3 (Prolyl hydroxylase domain-containing protein 3)

Beyond the preview

Go deeper on molidustat.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on molidustat.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call